8-K: Jasper Therapeutics Reports Q4 2025 Results, Advances Briquilimab

Jasper Therapeutics announced its fourth quarter and full-year 2025 financial results, alongside positive clinical data for briquilimab in chronic urticaria and asthma, with future study progress contingent on capital availability.

Summary

• Reported fourth quarter and full-year 2025 financial results, including a cash and cash equivalents balance of $28.7 million as of December 31, 2025.
• Announced positive updated data from briquilimab studies in chronic spontaneous urticaria (CSU), with 67% of additional patients in Cohort 9.1 of the BEACON study achieving a complete response at 12 weeks, and 75% of participants in the open-label extension achieving a complete response or well-controlled disease.
• Completed an internal investigation into anomalous July 2025 BEACON data, confirming no issues with the drug product and generating recommendations for enhanced site selection and patient screening criteria.
• Reported positive preliminary proof-of-concept data from the ETESIAN study of briquilimab in asthma, showing reductions in airway hyperresponsiveness and suppressed eosinophilic response.
• Jeet Mahal was appointed as Chief Executive Officer to lead the next phase of clinical growth.
• The company reported a net loss of $9.1 million for the three months ended December 31, 2025, and $75.8 million for the full year ended December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing with promising clinical data offset by a rapidly deteriorating financial position and explicit warnings about the need for capital to continue operations and clinical development.

Positives

• Positive updated clinical data for briquilimab in chronic spontaneous urticaria (CSU), with 67% of additional patients (n=6) in BEACON Cohort 9.1 achieving a complete response at 12 weeks with a mean UAS7 reduction of 31 points.
• 75% of CSU participants (n=36) in the open-label extension study achieved a complete response or well-controlled disease at 12 weeks.
• KIT-related adverse events were predominantly low-grade events that resolved while on study in the open-label extension, with a median follow-up of over 200 days on 63 participants.
• BEACON and open-label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU.
• The internal investigation into previous anomalous clinical response data confirmed no issues with the drug product utilized in the study.
• Positive preliminary proof-of-concept data for briquilimab in asthma, showing reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 and 12 weeks after a single 180mg dose.
• Jeet Mahal was appointed as Chief Executive Officer to lead the next phase of clinical growth.
• Research and development expense for Q4 2025 decreased to $11.4 million from $19.8 million in Q4 2024.
• General and administrative expense for Q4 2025 decreased to $4.5 million from $5.5 million in Q4 2024.

Negatives

• Cash and cash equivalents significantly decreased to $28.7 million as of December 31, 2025, from $71.6 million as of December 31, 2024.
• The full-year net loss increased to $75.8 million in 2025 from $71.3 million in 2024.
• Total stockholders' equity decreased substantially to $4.151 million as of December 31, 2025, from $61.674 million as of December 31, 2024.
• Advancement of the planned Phase 2b/3 study in CSU is explicitly stated as 'pending capital availability'.
• Advancing any future clinical studies in asthma is contingent on 'capital availability', competitive landscape, and potential strategic partnerships.
• The company's ability to continue as a going concern is highlighted as a risk due to potential inability to raise capital.

Risks

• Product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
• Clinical trials may not confirm any safety, potency, or other product characteristics described or assumed.
• Prior test, study, and trial results may not be replicated in continuing or future studies and trials.
• Inability to raise capital to continue operations and the Phase 2b/3 study in CSU.
• Inability to successfully market or gain market acceptance of product candidates.
• Product candidates may not be beneficial to patients or successfully commercialized.
• Patients' willingness to try new therapies and physicians' willingness to prescribe these therapies.
• Effects of competition on the business.
• Third parties on which the company depends for laboratory, clinical development, manufacturing, and other critical services may fail to perform satisfactorily.
• Business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics.
• Inability to obtain and maintain sufficient intellectual property protection for investigational products or infringement of the intellectual property protection of others.

Future Outlook

Jasper Therapeutics plans to commence patient enrollment in the Phase 2b portion of its planned Phase 2b/3 study in CSU in the second half of 2026, pending capital availability. Further development of briquilimab in asthma is also contingent on capital availability, competitive landscape, and potential strategic partnerships.

Management Comments

• "Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma."
• "We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study, which reaffirmed the potential of briquilimab to drive rapid and durable disease control in patients."
• "We are finalizing dose selection for the Phase 2b portion of our planned Phase 2b/3 study in CSU where we will evaluate two efficacious doses versus placebo to demonstrate the differentiated profile based on briquilimab's unique biological properties."
• "We remain on track to commence patient enrollment in the second half of 2026, pending capital availability."
• "The positive proof of concept data generated in the ETESIAN study supports further development in the broader asthma population; however, advancing any future clinical studies in asthma would be based on an evaluation of the competitive landscape, the potential for strategic partnerships and capital availability."

Industry Context

StockSavvy.ai notes that the positive clinical data for briquilimab in chronic urticaria and asthma positions Jasper Therapeutics in a competitive landscape for mast cell-driven diseases. The emphasis on a 'differentiated profile' suggests an attempt to stand out from existing therapies like Xolair (omalizumab) or newer biologics targeting IgE or IL-4/13 pathways, which are common in asthma and urticaria. However, the explicit mention of capital availability as a prerequisite for advancing studies highlights a common challenge for clinical-stage biotechs, especially those without a commercialized product, in a capital-intensive industry.

Comparison to Industry Standards

• The reported 67% complete response rate in a subset of CSU patients (n=6) and 75% complete response/well-controlled disease in the open-label extension (n=36) for briquilimab are promising, especially when compared to established treatments for CSU. For instance, Xolair (omalizumab) typically shows complete response rates around 30-40% in severe CSU patients who are refractory to antihistamines, with higher rates for well-controlled disease. Newer therapies like dupilumab (targeting IL-4/13) have also shown significant efficacy. Briquilimab's mechanism of mast cell depletion via c-Kit inhibition offers a potentially differentiated approach compared to IgE or cytokine pathway blockers.
• The proof-of-concept data in asthma, showing reductions in airway hyperresponsiveness and suppressed eosinophilic response, is a positive initial signal. However, the asthma market is highly competitive with multiple approved biologics (e.g., Xolair, Nucala, Fasenra, Dupixent, Tezspire) targeting various inflammatory pathways. Further development would need to demonstrate superior efficacy, safety, or a unique patient population benefit to compete effectively.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution if a capital raise occurs. Share price likely to be volatile due to promising clinical data but severe financial constraints and going concern risk.
• Patients: Continued development of briquilimab offers hope for new treatment options in chronic urticaria and asthma, but delays due to funding issues could impact availability.
• Employees: Uncertainty regarding the company's financial stability and ability to continue operations could impact job security.
• Creditors: Increased risk due to declining cash reserves and significant net losses.

Next Steps

• Finalize dose selection for the Phase 2b portion of the planned Phase 2b/3 study in CSU.
• Commence patient enrollment in the Phase 2b/3 study in CSU in the second half of 2026, pending capital availability.
• Evaluate the competitive landscape, potential for strategic partnerships, and capital availability for advancing future clinical studies in asthma.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, on or about March 30, 2026.

Key Dates

Recommendation

While the clinical data for briquilimab shows promise, the company's severe financial distress, evidenced by a significant drop in cash and equity, and explicit statements about future studies being "pending capital availability," present an immediate and substantial risk to its going concern status. The increasing net loss and rapid cash burn rate indicate an urgent need for capital, which could lead to significant dilution or even cessation of operations if not secured. The positive clinical data is overshadowed by the critical financial instability, making the stock a high-risk investment with a strong likelihood of further downside.

Keywords

Jasper Therapeutics, JSPR, Briquilimab, c-Kit, CD117, Chronic Spontaneous Urticaria, CSU, Chronic Inducible Urticaria, CIndU, Asthma, Biotechnology, Clinical Stage, Mast Cell Diseases, Financial Results, Q4 2025, Clinical Trials, Drug Development, Biopharma